Prepare for the GLOBE Model

Global Benchmark for Efficient Drug Pricing (GLOBE) Model

1 Need

- Medicare Part B spending is growing faster than overall drug spending
- Americans pay four times as much for brand-name drugs
- Medicare Part B spending must be reduced
- Preserving beneficiaries' quality of care is vital

2 Purpose

A new federal program designed to reduce out-of-pocket costs for Medicare Part B patients

3 Objectives

Test an alternative method for calculating Medicare Part B drug inflation rebates

Create a benchmark using international drug prices

4 Eligible patients

25%

of Medicare Part B beneficiaries, approximately, have Original Medicare as their primary payer

Reside in selected ZIP Code Tabulation Areas, as recorded in the CMS Medicare Beneficiary Database

5 Therapeutic categories

> $100 million in Original Medicare spending

- **Oncology**
- **Rheumatology**
- **Immunology**
- **Ophthalmology**
- **Endocrinology**

Possibly other categories

6 Drugs included

- High-spend
- Rebateable
- Single source
- Sole-source biologics
- Covered under Original Medicare Part B

7 Reference countries

Australia	Germany	South Korea
Austria	Ireland	Spain
Belgium	Israel	Sweden
Canada	Italy	Switzerland
Czech Republic	Japan	United Kingdom
Denmark	The Netherlands	
France	Norway	

8 Timing

23/12/2025	10/02/2026	1/1/2027	31/03/2032
Proposed rule	Final rule	Launch	Sunset

9 ICON services

- Forecast the impact on product demand and net revenue
- Predict changes in insurance coverage for the target patient population
- Develop communications for field teams, payers, providers, and patients

Contact ICON Market Access for more information

Submit an RFP

References

https://www.govinfo.gov/content/pkg/FR-2026-10-02/pdf/2026-20281.pdf
https://www.cms.gov/priorities/innovation/innovation-models/globe
https://www.cms.gov/priorities/innovation/globe-model-frequently-asked-questions

© 2026 ICON plc. All rights reserved.